ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...
Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback